XTX Topco’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$573K Buy
+28,435
New +$763K 0.01% 2258
2024
Q3
– Sell
-36,520
Closed -$593K – 2024
2024
Q2
$593K Buy
+36,520
New +$589K 0.05% 577
2024
Q1
– Sell
-12,961
Closed -$406K – 1776
2023
Q4
$406K Sell
12,961
-22,962
-64% -$548K 0.09% 389
2023
Q3
$749K Buy
+35,923
New +$976K 0.13% 194
2023
Q2
– Sell
-31,261
Closed -$588K – 1359
2023
Q1
$588K Buy
31,261
+6,686
+27% +$127K 0.12% 208
2022
Q4
$391K Sell
24,575
-14,096
-36% -$220K 0.08% 419
2022
Q3
$633K Buy
+38,671
New +$626K 0.16% 153
2021
Q3
– Sell
-11,903
Closed -$290K – 655
2021
Q2
$290K Buy
+11,903
New +$269K 0.1% 377

Other funds holding ACAD

XTX Topco's ACAD Position: Q3 2026 in Review

XTX Topco opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 28,435 shares worth $573K. The stake represents 0.01% of the portfolio and ranks #2258 among its holdings. This is a return to the name: XTX Topco previously reported a position in ACAD as recently as Q2 2024.

XTX Topco first reported a position in ACAD in Q2 2021 and has held it in 8 quarters since. The position peaked at $749K in Q3 2023. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • XTX Topco held 28,435 shares of Acadia Pharmaceuticals worth $573K as of Q3 2026.
  • Acadia Pharmaceuticals was a new XTX Topco position in Q3 2026.
  • Acadia Pharmaceuticals made up 0.01% of XTX Topco's portfolio in Q3 2026, its #2258 holding.
  • XTX Topco first reported a position in Acadia Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
  • XTX Topco's Acadia Pharmaceuticals position peaked at $749K in Q3 2023.
  • 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on XTX Topco's 13F filing for Q3 2026, filed 16 Nov 2026.